Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
复制标题
DOI：
10.3816/ccc.2003.n.006
复制
发表时间：
2003-02-01
影响因子：
3.4
通讯作者：
Cohen, Roger B
中科院分区：
文献类型：
--
作者：
Cohen, Roger B
表皮生长因子受体（EGFR）在晚期结直肠癌（CRC）中广泛表达，EGFR水平升高与这些患者的生存率呈负相关。两种一般策略已用于阻断EGFR信号传导：用抗EGFR单克隆抗体（例如，西妥昔单抗和ABX-EGF）阻止配体结合，并用小分子抑制其内在酪氨酸激酶（例如，吉非替尼[易瑞沙]和厄洛替尼[OSI-774，特罗凯]）。西妥昔单抗的II期临床试验表明，它可能是一种有效的治疗选择，单独或与标准疗法联合作为一线或二线治疗。已经报告了在CRC患者中评价其他EGFR抑制剂的I期研究。将抗EGFR治疗纳入标准治疗是当前临床试验的主题。
The epidermal growth factor receptor (EGFR) is widely expressed in advanced colorectal cancers (CRCs), and higher levels of EGFR are inversely related to survival in these patients. Two general strategies have been used to block EGFR signaling: preventing ligand binding with anti-EGFR monoclonal antibodies (eg, cetuximab and ABX-EGF) and inhibiting its intrinsic tyrosine kinase with small molecules (eg, gefitinib [Iressa] and erlotinib [OSI-774,Tarceva]). Phase II trials of cetuximab suggest that it might be an effective treatment option alone or in combination with standard therapies as first- or second-line therapy. Phase I studies evaluating other EGFR inhibitors in patients with CRC have been reported. The inclusion of anti-EGFR therapies into standard treatment is the subject of current clinical trials.